Allogeneic umbilical cord-derived mesenchymal stem cells for treating critical-sized bone defects: a translational study

Ismail Hadisoebroto Dilogo, Dina Rahmatika, Jeanne Adiwinata Pawitan, Isabella Kurnia Liem, Tri Kurniawati, Tera Kispa, Fajar Mujadid

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Introduction: The current ‘gold-standard’ treatment of critical-sized bone defects (CSBDs) is autografts; however, they have drawbacks including lack of massive bone source donor site morbidity, incomplete remodeling, and the risk of infection. One potential treatment for treating CSBDs is bone marrow-derived mesenchymal stem cells (BM-MSCs). Previously, there were no studies regarding the use of human umbilical cord-mesenchymal stem cells (hUC-MSCs) for treating BDs. We aim to investigate the use of allogeneic hUC-MSCs for treating CSBDs. Method: We included subjects who were diagnosed with non-union fracture with CSBDs who agreed to undergo hUC-MSCs implantation. All patients were given allogeneic hUC-MSCs. All MSCs were obtained and cultured using the multiple-harvest explant method. Subjects were evaluated functionally using the Lower Extremity Functional Scale (LEFS) and radiologically by volume defect reduction. Result: A total of seven (3 male, 4 female) subjects were recruited for this study. The subjects age ranged from 14 to 62 years. All seven subjects had increased LEFS during the end of the follow-up period, indicating improved functional ability. The follow-up period ranged from 12 to 36 months. One subject had wound dehiscence and infection, and two subjects developed partial union. Conclusion: Umbilical cord mesenchymal stem cells are a potential new treatment for CSBDs. Additional studies with larger samples and control groups are required to further investigate the safety and efficacy of umbilical cord-derived mesenchymal stem cells for treating CSBDs.

Original languageEnglish
Pages (from-to)265-273
Number of pages9
JournalEuropean Journal of Orthopaedic Surgery and Traumatology
Issue number2
Publication statusPublished - Feb 2021


  • Critical-sized bone defect
  • Mesenchymal stem cells
  • Umbilical cord


Dive into the research topics of 'Allogeneic umbilical cord-derived mesenchymal stem cells for treating critical-sized bone defects: a translational study'. Together they form a unique fingerprint.

Cite this